LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Brookdale Senior Living Reports May 2024 Occupancy

June 10, 2024 | Last Trade: US$6.61 0.54 8.90

NASHVILLE, Tenn., June 10, 2024 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for May 2024.

May 2024 Observations

  • Sequentially, May weighted average occupancy increased 20 basis points while month end occupancy increased 30 basis points, supported by ongoing improvement in resident retention.
  • May weighted average occupancy reflected a continued outperformance versus pre-pandemic normal seasonality and represented the Company's thirty-first consecutive month of year-over-year weighted average occupancy growth.
  • Second quarter-to-date weighted average occupancy increased 160 basis points to 78.0% compared to 76.4% for the comparable period of 2023.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 652 communities in 41 states as of March 31, 2024, with the ability to serve approximately 59,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

 
Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB